Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.
DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.
One of the main limiting factors for a traditional x-ray source is the thermal management of the solid fixed, or rotating, anode leading to overheating or even melting as the electron beam power is increased.
Controversy over the F.D.A.'s proposal to withdraw approval of Avastin for breast cancer treatment will reignite June 28-29 with a new round of hearings. One oncologist who will be monitoring the hearings is Dr. Frederick C. Tucker Jr. of Fredericksburg Oncology in Virginia, whose recent New York Times op ed defended the F.D.A.'s position on scientific grounds.
Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.
AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.
A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.
A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.
Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such resistance, but first they must understand why and how it happens.
Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.
Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.
Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.
Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.
Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.
Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events as outlined in the recently updated NCCN Guidelines™ for Breast Cancer. Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Breast Cancer, presented these and other notable updates to the NCCN Guidelines at the NCCN 16th Annual Conference on March 10, 2011.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.
Sermo, the world's largest online community for physicians, announced the publication of a free Sermo Report about how physicians are reacting to the FDA decision to rescind the indication for Avastin (bevacizumab) in the treatment of breast cancer.
A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.
After a spinal cord injury a number of factors impede the regeneration of nerve cells. Two of the most important of these factors are the destabilization of the cytoskeleton and the development of scar tissue.
In a study published today in Science, a global research team reports that the cancer drug Taxol promotes the regeneration of injured nerve cells in the central nervous system after spinal cord injury.